Great Lakes Advisors LLC Buys Shares of 44,048 DexCom, Inc. (NASDAQ:DXCM)

Great Lakes Advisors LLC acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 44,048 shares of the medical device company's stock, valued at approximately $3,426,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Sequoia Financial Advisors LLC boosted its holdings in shares of DexCom by 35.5% during the 4th quarter. Sequoia Financial Advisors LLC now owns 8,489 shares of the medical device company's stock valued at $660,000 after purchasing an additional 2,222 shares during the last quarter. AGF Management Ltd. bought a new position in shares of DexCom during the 4th quarter valued at about $599,000. King Luther Capital Management Corp boosted its holdings in shares of DexCom by 4.2% during the 4th quarter. King Luther Capital Management Corp now owns 222,132 shares of the medical device company's stock valued at $17,275,000 after purchasing an additional 8,887 shares during the last quarter. Marathon Trading Investment Management LLC bought a new position in shares of DexCom during the 4th quarter valued at about $1,217,000. Finally, Independent Advisor Alliance bought a new position in shares of DexCom during the 4th quarter valued at about $244,000. Institutional investors own 97.75% of the company's stock.

DexCom Trading Up 3.8 %

DXCM stock traded up $2.68 during mid-day trading on Wednesday, reaching $73.38. The company had a trading volume of 4,301,534 shares, compared to its average volume of 3,887,220. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The company has a market capitalization of $28.67 billion, a PE ratio of 51.31, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. The firm has a 50 day moving average of $83.64 and a 200 day moving average of $76.95. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00.

Remove Ads

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, equities analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares in the company, valued at approximately $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael Jon Brown sold 13,000 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $914,940.00. Following the transaction, the executive vice president now owns 105,602 shares in the company, valued at approximately $7,432,268.76. This represents a 10.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 104,657 shares of company stock worth $8,019,422. Corporate insiders own 0.30% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on DXCM. Morgan Stanley upped their target price on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Citigroup upped their target price on shares of DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a research report on Tuesday, March 4th. Canaccord Genuity Group upped their target price on shares of DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a research report on Friday, February 14th. Robert W. Baird upgraded shares of DexCom from a "neutral" rating to an "outperform" rating and upped their target price for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Finally, Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and upped their target price for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $99.82.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.